Novanta (NASDAQ:NOVT) Shares Gap Up on Better-Than-Expected Earnings

Shares of Novanta Inc. (NASDAQ:NOVT) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $153.12, but opened at $169.50. Novanta shares last traded at $172.3830, with a volume of 90,553 shares trading hands.

The technology company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.06. The company had revenue of $265.81 million during the quarter, compared to analysts’ expectations of $262.30 million. Novanta had a net margin of 5.35% and a return on equity of 12.06%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.76 EPS. Novanta has set its FY 2026 guidance at 3.680-3.740 EPS and its Q3 2026 guidance at 0.950-1.000 EPS.

Key Stories Impacting Novanta

Here are the key news stories impacting Novanta this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates: Novanta reported adjusted EPS of $0.89, up from $0.76 a year earlier and above the $0.83 analyst consensus. Revenue increased 10.3% year over year to $265.81 million, exceeding expectations of $262.30 million. Novanta Q2 Earnings Snapshot
• Positive Sentiment: Strong third-quarter outlook: Management forecast Q3 2026 EPS of $0.95 to $1.00, above the $0.94 consensus estimate. Revenue guidance of $300 million to $304 million was also well above analysts’ expectations of approximately $263.1 million, signaling accelerating growth. Novanta Announces Second-Quarter 2026 Results
• Positive Sentiment: Full-year EPS outlook raised above expectations: Novanta projected FY 2026 EPS of $3.68 to $3.74, ahead of the $3.59 analyst consensus. Full-year revenue guidance was approximately $1.1 billion, broadly consistent with expectations. Novanta Tops Q2 Earnings and Revenue Estimates
• Neutral Sentiment: Despite the favorable results, Novanta’s net margin was 5.35%, while its price-to-earnings ratio remains elevated at roughly 120, leaving the stock sensitive to any future slowdown or guidance reduction.

Analyst Upgrades and Downgrades

NOVT has been the topic of a number of research reports. Wall Street Zen downgraded Novanta from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Robert W. Baird set a $180.00 target price on Novanta in a report on Tuesday, June 9th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Novanta in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Novanta currently has an average rating of “Hold” and a consensus price target of $180.00.

Insider Activity at Novanta

In related news, CEO Matthijs Glastra sold 6,500 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $161.13, for a total transaction of $1,047,345.00. Following the transaction, the chief executive officer directly owned 29,761 shares of the company’s stock, valued at approximately $4,795,389.93. The trade was a 17.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Fifth Third Bancorp increased its stake in Novanta by 12.8% in the 1st quarter. Fifth Third Bancorp now owns 778 shares of the technology company’s stock worth $92,000 after purchasing an additional 88 shares in the last quarter. Assetmark Inc. lifted its stake in Novanta by 22.4% during the fourth quarter. Assetmark Inc. now owns 541 shares of the technology company’s stock valued at $64,000 after buying an additional 99 shares in the last quarter. State of Michigan Retirement System boosted its holdings in shares of Novanta by 1.2% in the first quarter. State of Michigan Retirement System now owns 8,600 shares of the technology company’s stock worth $1,016,000 after buying an additional 100 shares during the period. HB Wealth Management LLC increased its position in shares of Novanta by 9.0% in the first quarter. HB Wealth Management LLC now owns 1,989 shares of the technology company’s stock worth $235,000 after acquiring an additional 164 shares in the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of Novanta by 1.6% in the first quarter. Quantinno Capital Management LP now owns 10,746 shares of the technology company’s stock worth $1,269,000 after acquiring an additional 169 shares in the last quarter. 98.35% of the stock is currently owned by hedge funds and other institutional investors.

Novanta Price Performance

The stock’s fifty day moving average price is $153.85 and its 200-day moving average price is $141.21. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.56 and a quick ratio of 2.69. The firm has a market cap of $6.58 billion, a price-to-earnings ratio of 125.85 and a beta of 1.68.

About Novanta

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.